Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elisabetta Calistri

Showing results (11-20 of 20) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 20 results.
Cancer Medicine|October 8, 2022
BCR::ABL1 levels at first month after TKI discontinuation predict subsequent maintenance of treatment-free remission: A study from the "GRUPPO TRIVENETO LMC"Sara Di Giusto, Eleonora Toffoletti, Massimiliano Bonifacio, et al.
Targeted Oncology|October 18, 2021
Making Treatment-Free Remission (TFR) Easier in Chronic Myeloid Leukemia: Fact-Checking and Practical Management ToolsFausto Castagnetti, Gianni Binotto, Isabella Capodanno, et al.
Oncotarget|March 28, 2018
Excellent outcomes of 2G-TKI therapy after imatinib failure in chronic phase CML patientsMario Tiribelli, Massimiliano Bonifacio, Gianni Binotto, et al.
Annals of Hematology|July 18, 2025
Exploring thromboembolic risk factors in polycythemia vera: from current evidence to PROSPERO study designValerio De Stefano, Francesco Passamonti, Francesca Palandri, et al.
Drugs & Aging|May 18, 2013
Imatinib in very elderly patients with chronic myeloid leukemia in chronic phase: a retrospective studyRoberto Latagliata, Dario Ferrero, Alessandra Iurlo, et al.
Annals of Hematology|August 9, 2019
Outcome of very elderly chronic myeloid leukaemia patients treated with imatinib frontlineMonica Crugnola, Fausto Castagnetti, Massimo Breccia, et al.
Cancer|May 12, 2026
Clinical benefit and predictors of response to momelotinib after ruxolitinib failure: A cooperative real-world studyFrancesca Palandri, Monia Marchetti, Elena M Elli, et al.
Cancer|June 29, 2025
Chronic myeloid leukemia outcomes according to baseline risk and first-line treatment in real-world settings: Data from the Italian Network/CML CampusValentina Giai, Tiziana Rosso, Fausto Castagnetti, et al.
Oncotarget|September 1, 2016
Imatinib and polypharmacy in very old patients with chronic myeloid leukemia: effects on response rate, toxicity and outcomeAlessandra Iurlo, Alessandro Nobili, Roberto Latagliata, et al.
Blood|December 27, 2019
Prospective assessment of NGS-detectable mutations in CML patients with nonoptimal response: the NEXT-in-CML studySimona Soverini, Luana Bavaro, Caterina De Benedittis, et al.
Pageof 2

Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
Cancer Medicine|October 8, 2022
BCR::ABL1 levels at first month after TKI discontinuation predict subsequent maintenance of treatment-free remission: A study from the "GRUPPO TRIVENETO LMC"Sara Di Giusto, Eleonora Toffoletti, Massimiliano Bonifacio, et al.
Targeted Oncology|October 18, 2021
Making Treatment-Free Remission (TFR) Easier in Chronic Myeloid Leukemia: Fact-Checking and Practical Management ToolsFausto Castagnetti, Gianni Binotto, Isabella Capodanno, et al.
Oncotarget|March 28, 2018
Excellent outcomes of 2G-TKI therapy after imatinib failure in chronic phase CML patientsMario Tiribelli, Massimiliano Bonifacio, Gianni Binotto, et al.
Annals of Hematology|July 18, 2025
Exploring thromboembolic risk factors in polycythemia vera: from current evidence to PROSPERO study designValerio De Stefano, Francesco Passamonti, Francesca Palandri, et al.
Drugs & Aging|May 18, 2013
Imatinib in very elderly patients with chronic myeloid leukemia in chronic phase: a retrospective studyRoberto Latagliata, Dario Ferrero, Alessandra Iurlo, et al.
Annals of Hematology|August 9, 2019
Outcome of very elderly chronic myeloid leukaemia patients treated with imatinib frontlineMonica Crugnola, Fausto Castagnetti, Massimo Breccia, et al.
Cancer|May 12, 2026
Clinical benefit and predictors of response to momelotinib after ruxolitinib failure: A cooperative real-world studyFrancesca Palandri, Monia Marchetti, Elena M Elli, et al.
Cancer|June 29, 2025
Chronic myeloid leukemia outcomes according to baseline risk and first-line treatment in real-world settings: Data from the Italian Network/CML CampusValentina Giai, Tiziana Rosso, Fausto Castagnetti, et al.
Oncotarget|September 1, 2016
Imatinib and polypharmacy in very old patients with chronic myeloid leukemia: effects on response rate, toxicity and outcomeAlessandra Iurlo, Alessandro Nobili, Roberto Latagliata, et al.
Blood|December 27, 2019
Prospective assessment of NGS-detectable mutations in CML patients with nonoptimal response: the NEXT-in-CML studySimona Soverini, Luana Bavaro, Caterina De Benedittis, et al.
Pageof 2